about
Are pitch and roll compensations required in all pathologies? A data analysis of 2945 fractions.Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapyMonte Carlo simulation of TrueBeam flattening-filter-free beams using varian phase-space files: comparison with experimental data.Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments.Multi-institutional application of Failure Mode and Effects Analysis (FMEA) to CyberKnife Stereotactic Body Radiation Therapy (SBRT).Performance of a Knowledge-Based Model for Optimization of Volumetric Modulated Arc Therapy Plans for Single and Bilateral Breast Irradiation.Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience.Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy.Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderlyVolumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients.SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case.Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical resultsInitial experience of hypofractionated radiation retreatment with true beam and flattening filter free beam in selected case reports of recurrent nasopharyngeal carcinoma.Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments.Role of the technical aspects of hypofractionated radiation therapy treatment of prostate cancer: a review.Frontiers in planning optimization for lung SBRT.SBRT for prostate cancer: Challenges and features from a physicist prospective.RapidPlan head and neck model: the objectives and possible clinical benefit.Stereotactic radiosurgery for intracranial metastases: linac-based and gamma-dedicated unit approach.Dosimetric characterization of small fields using a plastic scintillator detector: A large multicenter study.CyberKnife beam output factor measurements: A multi-site and multi-detector study.Multicenter evaluation of a synthetic single-crystal diamond detector for CyberKnife small field size output factors.Accuracy evaluation of the optical surface monitoring system on EDGE linear accelerator in a phantom study.Applying failure mode effects and criticality analysis in radiotherapy: lessons learned and perspectives of enhancement.Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases.Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors.11C choline PET guided salvage radiotherapy with volumetric modulation arc therapy and hypofractionation for recurrent prostate cancer after HIFU failure: preliminary results of tolerability and acute toxicityStereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations.Dosimetric validation of the Acuros XB Advanced Dose Calculation algorithm: fundamental characterization in water.Internal target volume defined by contrast-enhanced 4D-CT scan in unresectable pancreatic tumour: evaluation and reproducibility.Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy.Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft-tissue sarcoma radiotherapy.Interplay effects between dose distribution quality and positioning accuracy in total marrow irradiation with volumetric modulated arc therapy.Pretreatment quality assurance of flattening filter free beams on 224 patients for intensity modulated plans: a multicentric study.Cranio-spinal irradiation with volumetric modulated arc therapy: a multi-institutional treatment experience.
P50
Q30995530-DCA217CB-9FA9-403D-B915-CEF4EDFBB607Q33398899-9A1E0300-BDBE-460E-AF8E-64A62DF1D083Q34196471-95F2A3D8-5C21-426F-9ABA-F4A2CEABDA22Q34584811-E1E3216B-0CD5-41BB-B27F-150DEE1C7B05Q35160392-74EBCFFB-E7C4-480C-803D-9BBC3E45AF5EQ35232033-093C2D90-95F1-4568-ADB5-A11AFCBAED2FQ35748678-284F6EA0-6AF6-43EA-926E-2D14E73981CFQ35874856-C3A4709D-8C7C-4B28-B92E-21F90A0B56F2Q35886218-1F97215F-2C71-4F5F-A545-F7D8DF711FA5Q36259231-70C876DA-A8D9-4E3C-B08F-A36728161C14Q36368120-248100DE-7159-47C6-85F2-BB81D2AD3CA0Q36535570-9EC3F4A8-CD27-4DE1-A2B8-166280B59315Q36550917-DB6C73D4-5275-4434-B5C7-7468A604153BQ36552596-B38E2DE6-8F2C-4103-83B3-ED562B0E2A00Q37000899-96F65ABE-511F-4542-AD9A-4F7F597AA280Q37038061-4447910F-B7D0-435F-AA10-765BDDF9BCA3Q37263260-BA8B680E-6120-4704-994D-B52501122B20Q37453956-D0188770-A6EF-4CB6-BD07-DDC0B03CD451Q37723610-03662553-2AF4-4D9B-9FF2-F1EA729A2A9AQ38402011-F6DDB7FA-5209-4CE8-AF76-485201283DE3Q38752749-8D23FE08-D7A5-406F-8EDC-DFCB18E88AD2Q38803177-0031360A-0064-497C-B56E-101ECC19B7E0Q38816399-9021D2CE-BFEF-493D-B950-CE6EDD2C007DQ38836152-2A175527-6DF3-40CA-A0AF-120660A331F6Q38849306-F1B7967A-E73F-4CFD-BA57-C60B7EBDE5B7Q39514830-0EC9166B-C6AD-43E5-BF6C-93C9F9761CF3Q39859320-FBF5A3AE-AD26-437E-A77A-3D448543F497Q39905044-60AA937B-E241-44DC-99E1-43D64E4F26CFQ39905108-514E83ED-FE4A-4350-91E9-216E32EC690DQ40651962-4A8B57D6-AD38-439F-AA7D-0DE5FD7AD0E9Q41421285-E2F6B0F0-40EB-4076-85D2-79B8A42A0CC3Q42424146-BBEE1728-A661-49D2-ADA9-3A4867AA7624Q42608693-31308B1D-3917-43EC-82F4-80E3FC6ED581Q42692650-5AF5FD07-AB55-4D33-9AC4-5865B9B06790Q42913556-E4641CC7-620D-438D-BB00-E5795D5B6D8CQ43677664-C51A0381-FFB0-4B91-97C1-AF3F86FE898CQ43850546-4707AC17-6B9F-4832-B36A-F9B55DC8027EQ43973614-773AE196-8186-428B-80AC-1F23AE262DD0Q44254999-AF59931D-CD18-4DBB-A5C5-68DE0C33006DQ45175350-42E372FA-8A9C-45FE-A905-9A2E35C7D41C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pietro Mancosu
@ast
Pietro Mancosu
@en
Pietro Mancosu
@es
Pietro Mancosu
@nl
Pietro Mancosu
@pt
Pietro Mancosu
@sl
type
label
Pietro Mancosu
@ast
Pietro Mancosu
@en
Pietro Mancosu
@es
Pietro Mancosu
@nl
Pietro Mancosu
@pt
Pietro Mancosu
@sl
prefLabel
Pietro Mancosu
@ast
Pietro Mancosu
@en
Pietro Mancosu
@es
Pietro Mancosu
@nl
Pietro Mancosu
@pt
Pietro Mancosu
@sl
P106
P1153
24451642900
P21
P31
P496
0000-0002-0165-7931